drugset / Trial / NCT01602939
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Cladribine plus Pegylated Interpheron alpha-2a therapy in patients with advanced systemic mastocytosis carrying D816V or other exon 17 KIT mutations.
Timeline
- Start
- 2012-05
- Primary completion
- 2017-02
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | 0.07 mg/kg | Subcutaneous |
| Subject | Cladribine | Small molecule | 0.14 mg/kg | Subcutaneous |
| Subject | pegylated interpheron alpha-2a | Unknown | 1 ug/kg | Subcutaneous |